β,β-Dimethylacrylshikonin (Synonyms: Isoarnebin I)

目錄號(hào): HY-N5112B 純度: 99.30%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

β,β-Dimethylacrylshikonin (Isoarnebin I) 是從紫草中提取得到的一種萘醌衍生物，通過PI3K通路誘導(dǎo) eNOS、VEGF 和 HIF-1α 的表達(dá)，促進(jìn)血管生成。β,β-Dimethylacrylshikonin 具有抗腫瘤活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

β,β-Dimethylacrylshikonin Chemical Structure

CAS No. : 24502-79-2

1. 客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
5 mg	￥550	In-stock
10 mg	￥950	In-stock
25 mg	￥2000	In-stock
50 mg		詢價(jià)
100 mg		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of β,β-Dimethylacrylshikonin:

β,β-Dimethylacrylalkannin In-stock

MCE 顧客使用本產(chǎn)品發(fā)表的 1 篇科研文獻(xiàn)

•Phytomedicine. 2023 Mar 15;114:154769. [Abstract]

β,β-Dimethylacrylshikonin 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HIF/HIF Prolyl-Hydroxylase 亞型特異性產(chǎn)品:

查看所有亞型

HIF-1α HIF

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

β,β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative isolated from Lithospermum erythrorhizon Sieb. et Zucc. , promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway.β,β-Dimethylacrylshikonin has anti-tumor activity^[1].

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
B16-F0	IC₅₀	1.2 μM Compound: DMAS	Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31961147]
B16-F0	IC₅₀	1.2 μM Compound: DMAS	Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31961147]
CCRF-CEM	IC₅₀	1.9 μM Compound: 3	Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay	[PMID: 22530779]
HCT-116	IC₅₀	20 μM Compound: 3	Cytotoxicity against human HCT116 cells after 72 hrs by XTT assay Cytotoxicity against human HCT116 cells after 72 hrs by XTT assay	[PMID: 22530779]
MDA-MB-231	IC₅₀	23.2 μM Compound: 3	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by XTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by XTT assay	[PMID: 22530779]
MRC5	IC₅₀	2.4 μM Compound: 3	Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay	[PMID: 22530779]
MRC5	IC₅₀	9.5 μM Compound: DMAS	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel1	IC₅₀	1 μM Compound: DMAS	Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel1	IC₅₀	1.1 μM Compound: DMAS	Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel1	IC₅₀	1.9 μM Compound: DMAS	Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel2	IC₅₀	1.7 μM Compound: DMAS	Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel2	IC₅₀	2.3 μM Compound: DMAS	Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel2	IC₅₀	5.1 μM Compound: DMAS	Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
MUGMel2	IC₅₀	7.2 μM Compound: 1-76	Antitumor activity against human MUG-Mel2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antitumor activity against human MUG-Mel2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 35367708]
SBcl2	IC₅₀	1.1 μM Compound: 1-76	Antitumor activity against human SBcl2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antitumor activity against human SBcl2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 35367708]
SBcl2	IC₅₀	1.1 μM Compound: 3	Cytotoxicity against human SBcl2 cells after 72 hrs by XTT assay Cytotoxicity against human SBcl2 cells after 72 hrs by XTT assay	[PMID: 22530779]
SBcl2	IC₅₀	1.1 μM Compound: DMAS	Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
SBcl2	IC₅₀	1.2 μM Compound: DMAS	Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
SBcl2	IC₅₀	1.9 μM Compound: DMAS	Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
U-251	IC₅₀	30.8 μM Compound: 3	Cytotoxicity against human U251 cells after 72 hrs by XTT assay Cytotoxicity against human U251 cells after 72 hrs by XTT assay	[PMID: 22530779]
WM164	IC₅₀	2.4 μM Compound: DMAS	Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM164	IC₅₀	3 μM Compound: DMAS	Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM164	IC₅₀	3.8 μM Compound: DMAS	Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM164	IC₅₀	8.3 μM Compound: 1-76	Antitumor activity against human WM164 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antitumor activity against human WM164 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 35367708]
WM164	IC₅₀	8.3 μM Compound: 3	Cytotoxicity against human WM164 cells after 72 hrs by XTT assay Cytotoxicity against human WM164 cells after 72 hrs by XTT assay	[PMID: 22530779]
WM793	IC₅₀	0.7 μM Compound: DMAS	Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM793	IC₅₀	0.8 μM Compound: DMAS	Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]
WM793	IC₅₀	1.2 μM Compound: DMAS	Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method	[PMID: 31961147]

分子量

370.40

Formula

C₂₁H₂₂O₆

CAS 號(hào)

24502-79-2

性狀

固體

顏色

Brown to reddish brown

結(jié)構(gòu)分類

初始來源

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 12.5 mg/mL (33.75 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	2.6998 mL	13.4989 mL	26.9978 mL
5 mM	0.5400 mL	2.6998 mL	5.3996 mL
10 mM	0.2700 mL	1.3499 mL	2.6998 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

純度 & 產(chǎn)品資料

純度: 99.30%

選擇批次：

Data Sheet (606 KB) SDS (762 KB)

COA (199 KB) LCMS (88 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Zeng Z, et al. Arnebin-1 promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. Int J Mol Med. 2015 Sep;36(3):685-97. [Content Brief]

[2]. Sidhu GS, et al. Arnebin-1 accelerates normal and hydrocortisone-induced impaired wound healing. J Invest Dermatol. 1999 Nov;113(5):773-81. [Content Brief]

β,β-Dimethylacrylshikonin 相關(guān)分類

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6998 mL	13.4989 mL	26.9978 mL	67.4946 mL
	5 mM	0.5400 mL	2.6998 mL	5.3996 mL	13.4989 mL
	10 mM	0.2700 mL	1.3499 mL	2.6998 mL	6.7495 mL
	15 mM	0.1800 mL	0.8999 mL	1.7999 mL	4.4996 mL
	20 mM	0.1350 mL	0.6749 mL	1.3499 mL	3.3747 mL
	25 mM	0.1080 mL	0.5400 mL	1.0799 mL	2.6998 mL
	30 mM	0.0900 mL	0.4500 mL	0.8999 mL	2.2498 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

β,β-Dimethylacrylshikonin24502-79-2Isoarnebin IHIF/HIF Prolyl-HydroxylaseHypoxia-inducible factorsHIFsHIF-PHInhibitorinhibitorinhibit

您最近查看的產(chǎn)品:

產(chǎn)品名稱：

* 需求量：

* 客戶姓名：

* Email：

* 電話：

* 公司或機(jī)構(gòu)名稱：

留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。

站點(diǎn)地圖隱私聲明

滬ICP備15051369號(hào)-4

上海工商

滬公網(wǎng)安備31011502019417

滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS)

營(yíng)業(yè)執(zhí)照（三證合一）

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

β,β-Dimethylacrylshikonin (Synonyms: Isoarnebin I)

Customer Review

Other Forms of β,β-Dimethylacrylshikonin:

MCE 顧客使用本產(chǎn)品發(fā)表的 1 篇科研文獻(xiàn)